At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 308 enrolled
Drug / intervention
Duloxetine +1 moredrug
Likely dose
Duloxetine 30 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind Comparison of Duloxetine 30 mg QD and Placebo in Adult Patients With Fibromyalgia
In Brief
A Phase 4 clinical trial evaluating Duloxetine and Placebo for Fibromyalgia, Primary and Fibromyalgia, Secondary. Completed, enrolled 308 participants across 4 sites.
Detailed Summary
The main purpose of this study is to determine if 30 milligrams (mg) of duloxetine is effective in the treatment of fibromyalgia compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia, Primary, Fibromyalgia, Secondary
CountriesMexico
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartSep 2009
Primary CompletionNov 2010
TodayJul 2026
First PostedAug 25, 2009
Enrollment StartSep 1, 2009
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.9 years ago
Interventions
Duloxetinedrug
30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks
Placebodrug
QD po at the same time each day for 12 weeks